Membrane transporter NaPi2b (SCL34A2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
US9701755B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 22, 2015 |
| Grant date | Jul 11, 2017 |
| Priority date | — |
| Expiry date | Apr 22, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.